Advertisement
U.S. markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
2.0800+0.0200 (+0.97%)
At close: 04:00PM EST
2.0800 0.00 (0.00%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.0600
Open2.0400
Bid2.0500 x 100
Ask2.1300 x 100
Day's Range2.0200 - 2.2450
52 Week Range1.1650 - 2.4400
Volume333,047
Avg. Volume144,117
Market Cap122.477M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-1.0300
Earnings DateNov 08, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.74
  • Insider Monkey

    Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

    We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where InflaRx N.V. (NASDAQ:IFRX) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]

  • GlobeNewswire

    InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

    JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respirato